Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPSOS: Atezolizumab in Platinum-Ineligible NSCLC
NCT03191786Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2017
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Overall Survival up to 55 months. Started Sep 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03191786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191786.